Opaleye Management Reports New 9.99% Stake in Pasithea Therapeutics Corp. (KTTA)

On April 8, 2026, Opaleye Management Inc., Opaleye, L.P., and James Silverman filed a Schedule 13G regarding their holdings in Pasithea Therapeutics Corp. (KTTA). The filing reveals that the reporting group has acquired a 9.99% stake in the company, representing 2,491,000 shares of Common Stock. This position is held directly by the Fund (Opaleye, L.P.), with Opaleye Management Inc. serving as the investment adviser and James Silverman exercising control over the adviser. The event triggering this filing occurred on April 1, 2026. The reporting persons have certified that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The ownership calculation is based on approximately 24.94 million shares outstanding as reported in the issuer's most recent Form 10-K. This filing marks a significant new position for the Opaleye group in the clinical-stage biotechnology company.